HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

被引：151

作者：

Joura, Elmar A. ^{[1
]}

Kjaer, Susanne K. ^{[2
]}

Wheeler, Cosette M. ^{[3
,4
]}

Sigurdsson, Kristjan ^{[5
]}

Iversene, Ole-Erik ^{[6
,7
]}

Hernandez-Avila, Mauricio ^{[8
]}

Perez, Gonzalo ^{[9
]}

Brown, Darron R. ^{[10
]}

Koutsky, Laura A. ^{[11
]}

Tay, Eng Hseon ^{[12
]}

Garcia, Patricia ^{[13
]}

Ault, Kevin A. ^{[14
]}

Garland, Suzanne M. ^{[15
,16
]}

Leodolter, Sepp

Olssonn, Sven-Eric ^{[17
]}

Tang, Grace W. K. ^{[18
]}

Ferris, Daron G. ^{[19
]}

Paavonen, Jorma ^{[20
]}

Lehtinen, Matti ^{[21
]}

Steben, Marc ^{[22
]}

Bosch, Xavier ^{[23
]}

Dillner, Joakim ^{[24
]}

Kurmanv, Robert J. ^{[25
,26
]}

Majewski, Slawomir ^{[27
]}

Munoz, Nubia ^{[28
]}

Myers, Evan R. ^{[29
]}

Villa, Luisa L. ^{[30
]}

Taddeo, Frank J. ^{[31
]}

Roberts, Christine ^{[31
]}

Tadesse, Amha ^{[31
]}

Bryan, Janine ^{[31
]}

Lupinaccia, Lisa C. ^{[31
]}

Giacoletti, Katherine E. D. ^{[31
]}

Lu, Shuang ^{[31
]}

Vuocolo, Scott ^{[31
]}

Hesley, Teresa M. ^{[31
]}

Haupt, Richard M. ^{[31
]}

Barr, Eliav ^{[31
]}

机构：

[1] Med Univ Vienna, AKH, Dept Obstet & Gynecol, Div Gynecol Oncol, A-1020 Vienna, Austria

[2] Rigshosp, Danish Canc Soc, Inst Canc Epidemiol, Dept Virus Hormones & Canc, DK-2100 Copenhagen, Denmark

[3] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA

[4] Univ New Mexico, Dept Obstet & Gynaecol, Albuquerque, NM 87131 USA

[5] Natl Canc Detect Clin, Reykjavik, Iceland

[6] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway

[7] Univ Bergen, Dept Clin Med, Bergen, Norway

[8] Inst Publ Hlth, Cuernavaca, Morelos, Mexico

[9] Univ Rosario, Bogota, Colombia

[10] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA

[11] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[12] KK Womens & Childrens Hosp, Singapore, Singapore

[13] Univ Peruana Cayetano Heredia, Epidemiol HIV & STD Unit, Lima, Peru

[14] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA

[15] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[16] Royal Hosp Women, Dept Microbiol & Infect Dis, Melbourne, Vic, Australia

[17] Danderyd Hosp, Karolinska Inst, Stockholm, Sweden

[18] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China

[19] Med Coll Georgia, Dept Family Med & Obstet & Gynecol, Augusta, GA 30912 USA

[20] Univ Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland

[21] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[22] Inst Natl Sante Publ Quebec, Direct Risques Biol Environnementaux & Occupation, Montreal, PQ, Canada

[23] IDIBELL, Inst Catala Oncol, Barcelona, Spain

[24] Lund Univ, Dept Med Microbiol, S-22100 Lund, Sweden

[25] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA

[26] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD USA

[27] Warsaw Med Univ, Dept Dermatol & Venerol, Ctr Diagnost & Treatment Sexually Transmitted Dis, Warsaw, Poland

[28] Natl Canc Inst, Bogota, Colombia

[29] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA

[30] Ludwig Inst Canc Res, Dept Virol, Sao Paulo, Brazil

[31] Merck Res Labs, West Point, PA USA

来源：

VACCINE | 2008年 / 26卷 / 52期

关键词：

Human Papillomavirus; Humoral immunity; Immune memory;

D O I：

10.1016/j.vaccine.2008.09.073

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day I and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：6844 / 6851

页数：8

共 31 条

[11] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].

Garland, Suzanne M. ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Harper, Diane M. ;

Leodolter, Sepp ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Bryan, Janine ;

Taddeo, Frank J. ;

Railkar, Radha ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John ;

Sattler, Carlos ;

Barr, Eliav ;

Koutsky, Laura A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943

[12] HUMAN PAPILLOMAVIRUS TYPE-6 AND TYPE-11 DNA-SEQUENCES IN GENITAL AND LARYNGEAL PAPILLOMAS AND IN SOME CERVICAL CANCERS [J].

GISSMANN, L ;

WOLNIK, L ;

IKENBERG, H ;

KOLDOVSKY, U ;

SCHNURCH, HG ;

ZURHAUSEN, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (02) :560-563

[13] Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine [J].

Giuliano, Anna R. ;

Lazcano-Ponce, Eduardo ;

Villa, Luisa ;

Nolan, Terry ;

Marchant, Colin ;

Radley, David ;

Golm, Greg ;

McCarroll, Kathleen ;

Yu, Jimmy ;

Esser, Mark T. ;

Vuocolo, Scott C. ;

Barr, Eliav .

JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (08) :1153-1162

[14] High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia [J].

Goffin, F ;

Mayrand, MH ;

Gauthier, P ;

Alobaid, A ;

Lussier, C ;

Provencher, D ;

Drouin, P ;

Franco, EL ;

Coutlee, F .

JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (06) :814-819

[15] Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts [J].

Gross, G ;

Pfister, H .

MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2004, 193 (01) :35-44

[16] Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials [J].

Joura, Elmar A. ;

Leodolter, Sepp ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Koutsky, Laura A. ;

Garland, Suzanne M. ;

Harper, Diane M. ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Jones, Ronald W. ;

Bryan, Janine ;

Taddeo, Frank J. ;

Bautista, Oliver M. ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John W. ;

Sattler, Carlos ;

Barr, Eliav ;

Paavonen, Jorma .

LANCET, 2007, 369 (9574) :1693-1702

[17]

Kashima HK, 1996, OBSTET GYN CLIN N AM, V23, P699

[18] Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization [J].

Kirnbauer, R ;

Chandrachud, LM ;

ONeil, BW ;

Wagner, ER ;

Grindlay, GJ ;

Armstrong, A ;

McGarvie, GM ;

Schiller, JT ;

Lowy, DR ;

Campo, MS .

VIROLOGY, 1996, 219 (01) :37-44

[19] A controlled trial of a human papillomavirus type 16 vaccine [J].

Koutsky, LA ;

Ault, KA ;

Wheeler, CM ;

Brown, DR ;

Barr, E ;

Alvarez, FB ;

Chiacchierini, LM ;

Jansen, KU .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651

[20]

Koutsky Laura, 1997, American Journal of Medicine, V102, P3

← 1 2 3 4 →